FAT1 acts as an upstream regulator of oncogenic and inflammatory pathways, via PDCD4, in glioma cells

Oncogene

Volumn 32, Issue 33, 2013, Pages 3798-3808

  Dikshit, B ^a   Irshad, K ^a   Madan, E ^a   Aggarwal, N ^a   Sarkar, C ^a   Chandra, P S ^a   Gupta, D K ^a   Chattopadhyay, P ^a   Sinha, S ^a,b   Chosdol, K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b National Brain Research Center (NBRC)   (India)

Author keywords

AP 1; COX 2; FAT1; glioma; inflammation; PDCD4

Indexed keywords

COMPLEMENTARY DNA; CYCLOOXYGENASE 2; FAT1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MEMBRANE PROTEIN; PROGRAMMED CELL DEATH 4; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATTENUATION; CANCER CELL CULTURE; CANCER GRADING; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DROSOPHILA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSCRIPTION; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CADHERINS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION;

HOMO SAPIENS;

EID: 84882448827     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.393     Document Type: Article

References (104)

1. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010; 20: 65-71.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
3. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 2010; 87: 504-508.
4. Mandal RK, Mittal RD. Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort. Arch Med Res 42: 620-626.
5. Garodia P, Ichikawa H, Malani N, Sethi G, Aggarwal BB. From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer. J Soc Integr Oncol 2007; 5: 25-37.
6. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9: 351-369.
7. Borrello MG, Degl'Innocenti D, Pierotti MA. Inflammation and cancer: the oncogene-driven connection. Cancer Lett 2008; 267: 262-270.
8. Lim SK, Llaguno SR, McKay RM, Parada LF. Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep 2011; 44: 158-164.
9. Munshi A, Jalali R. Therapy for glioma: Indian perspective. Indian J Cancer 2009; 46: 127-131.
10. Alves TR, Lima FR, Kahn SA, Lobo D, Dubois LG, Soletti R et al. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci 2011; 89: 532-539.
11. Teodorczyk M, Martin-Villalba A. Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol 2010; 222: 1-10.
12. Noble M, Mayer-Proschel M. Growth factors, glia and gliomas. J Neurooncol 1997; 35: 193-209.
13. Tafani M, Di Vito M, Frati A, Pellegrini L, De Santis E, Sette G et al. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J Neuroinflammation 2011; 8: 32.
14. Goldbrunner RH, Bernstein JJ, Tonn JC. ECM-mediated glioma cell invasion. Microsc Res Tech 1998; 43: 250-257.
15. Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 2010; 87: 401-406.
16. Deorukhkar A, Krishnan S. Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 2010; 80: 1904-1914.
17. de Visser KE, Jonkers J. Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr Pharm Des 2009; 15: 1844-1853.
18. Tewari R, Choudhury SR, Ghosh S, Mehta VS, Sen E. Involvement of TNFalpha-induced TLR4-NF-kappaB and TLR4-HIF-1alpha feed-forward loops in the regulation of inflammatory responses in glioma. J Mol Med (Berl) 2012; 90: 67-80.
19. Chiu WT, Shen SC, Chow JM, Lin CW, Shia LT, Chen YC. Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERKdependent COX-2/PGE(2) activation. Neurobiol Dis 2009; 37: 118-129.
20. Sharma V, Dixit D, Ghosh S, Sen E. COX-2 regulates the proliferation of glioma stem like cells. Neurochem Int 2011; 59: 567-571.
21. Krakauer T. Molecular therapeutic targets in inflammation: cyclooxygenase and NF-kappaB. Curr Drug Targets Inflamm Allergy 2004; 3: 317-324.
22. Dunne J, Hanby AM, Poulsom R, Jones TA, Sheer D, Chin WG et al. Molecular cloning and tissue expression of FAT, the human homologue of the Drosophila fat gene that is located on chromosome 4q34-q35 and encodes a putative adhesion molecule. Genomics 1995; 30: 207-223.
23. Katoh Y, Katoh M. Comparative integromics on FAT1, FAT2, FAT3 and FAT4. Int J Mol Med 2006; 18: 523-528.
24. Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R, Irvine KD. Delineation of a Fat tumor suppressor pathway. Nat Genet 2006; 38: 1142-1150.
25. Reddy BV, Irvine KD. The Fat and Warts signaling pathways: new insights into their regulation, mechanism and conservation. Development 2008; 135: 2827-2838.
26. Silva E, Tsatskis Y, Gardano L, Tapon N, McNeill H. The tumor-suppressor gene fat controls tissue growth upstream of expanded in the hippo signaling pathway. Curr Biol 2006; 16: 2081-2089.
27. Willecke M, Hamaratoglu F, Kango-Singh M, Udan R, Chen CL, Tao C et al. The fat cadherin acts through the hippo tumor-suppressor pathway to regulate tissue size. Curr Biol 2006; 16: 2090-2100.
28. Bennett FC, Harvey KF. Fat cadherin modulates organ size in Drosophila via the Salvador/Warts/Hippo signaling pathway. Curr Biol 2006; 16: 2101-2110.
29. Mao Y, Rauskolb C, Cho E, Hu WL, Hayter H, Minihan G et al. Dachs: an unconventional myosin that functions downstream of Fat to regulate growth, affinity and gene expression in Drosophila. Development 2006; 133: 2539-2551.
30. Mahoney PA, Weber U, Onofrechuk P, Biessmann H, Bryant PJ, Goodman CS. The fat tumor suppressor gene in Drosophila encodes a novel member of the cadherin gene superfamily. Cell 1991; 67: 853-868.
31. Kwaepila N, Burns G, Leong AS. Immunohistological localisation of human FAT1 (hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in pathogenesis? Pathology 2006; 38: 125-131.
32. de Bock CE, Ardjmand A, Molloy TJ, Bone SM, Johnstone D, Campbell DM et al. The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia. Leukemia 2011; 26: 918-926.
33. Nishikawa Y, Miyazaki T, Nakashiro K, Yamagata H, Isokane M, Goda H et al. Human FAT1 cadherin controls cell migration and invasion of oral squamous cell carcinoma through the localization of beta-catenin. Oncol Rep 2011; 26: 587-592.
34. Nakaya K, Yamagata HD, Arita N, Nakashiro KI, Nose M, Miki T et al. Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array. Oncogene 2007; 26: 5300-5308.
35. Bendavid C, Pasquier L, Watrin T, Morcel K, Lucas J, Gicquel I et al. Phenotypic variability of a 4q34-4qter inherited deletion: MRKH syndrome in the daughter, cardiac defect and Fallopian tube cancer in the mother. Eur J Med Genet 2007; 50: 66-72.
36. Chosdol K, Misra A, Puri S, Srivastava T, Chattopadhyay P, Sarkar C et al. Frequent loss of heterozygosity and altered expression of the candidate tumor suppressor gene 'FAT' in human astrocytic tumors. BMC Cancer 2009; 9: 5.
37. Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell 2009; 101: 309-317.
38. Lankat-Buttgereit B, Goke R. Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy? Biol Cell 2003; 95: 515-519.
39. Waters LC, Strong SL, Ferlemann E, Oka O, Muskett FW, Veverka V et al. Structure of the tandem MA-3 region of Pdcd4 protein and characterization of its interactions with eIF4A and eIF4G: molecular mechanisms of a tumor suppressor. J Biol Chem 2011; 286: 17270-17280.
40. Gao F, Zhang P, Zhou C, Li J, Wang Q, Zhu F et al. Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol Rep 2007; 17: 123-128.
41. Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 2003; 200: 640-646.
42. Santhanam AN, Baker AR, Hegamyer G, Kirschmann DA, Colburn NH. Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion. Oncogene 2010; 29: 3921-3932.
43. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008; 27: 4373-4379.
44. Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep 2007; 18: 1387-1393.
45. Wang Q, Sun Z, Yang HS. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene 2008; 27: 1527-1535.
46. Yasuda M, Schmid T, Rubsamen D, Colburn NH, Irie K, Murakami A. Downregulation of programmed cell death 4 by inflammatory conditions contributes to the generation of the tumor promoting microenvironment. Mol Carcinog 2010; 49: 837-848.
47. Schmid T, Bajer MM, Blees JS, Eifler LK, Milke L, Rubsamen D et al. Inflammationinduced loss of Pdcd4 is mediated by phosphorylation-dependent degradation. Carcinogenesis 2011; 32: 1427-1433.
48. Yang HS, AP Jansen, Nair R, Shibahara K, Verma AK, Cmarik JL et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NFkappaB or ODC transactivation. Oncogene 2001; 20: 669-676.
49. Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol 2006; 26: 1297-1306.
50. Bitomsky N, Bohm M, Klempnauer KH. Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene 2004; 23: 7484-7493.
51. Fleenor DL, Pang IH, Clark AF. Involvement of AP-1 in interleukin-1alpha-stimulated MMP-3 expression in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2003; 44: 3494-3501.
52. Tsuji F, Seki I, Aono H, Odani N, Mizutani K, Okamoto M et al. Bucillamine mechanism inhibiting IL-1beta-induced VEGF production from fibroblast-like synoviocytes. Int Immunopharmacol 2007; 7: 1569-1576.
53. Bhattacharya A, Lakka SS, Mohanam S, Boyd D, Rao JS. Regulation of the urokinase- type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin Cancer Res 2001; 7: 267-276.
54. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT et al. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 2008; 27: 366-377.
55. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. The activator protein-1 transcription factor in respiratory epithelium carcinogenesis. Mol Cancer Res 2007; 5: 109-120.
56. Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L et al. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 2000; 36: 1640-1648.
57. Leaner VD, Kinoshita I, Birrer MJ. AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets. Oncogene 2003; 22: 5619-5629.
58. Leaner VD, Chick JF, Donninger H, Linniola I, Mendoza A, Khanna C et al. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am J Pathol 2009; 174: 265-275.
59. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002; 21: 7680-7689.
60. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res 2005; 65: 11282-11286.
61. Wang WQ, Zhang H, Wang HB, Sun YG, Peng ZH, Zhou G et al. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway. Mol Diagn Ther 2010; 14: 155-161.
62. Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003; 22: 3712-3720.
63. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 1988; 55: 875-885.
64. Schonthal A, Srinivas S, Eckhart W. Induction of c-jun protooncogene expression and transcription factor AP-1 activity by the polyoma virus middle-sized tumor antigen. Proc Natl Acad Sci USA 1992; 89: 4972-4976.
65. Fuchs SY, Dolan L, Davis RJ, Ronai Z. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene 1996; 13: 1531-1535.
66. Fuchs SY, Xie B, Adler V, Fried VA, Davis RJ, Ronai Z. c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors. J Biol Chem 1997; 272: 32163-32168.
67. Zhang Z, DuBois RN. Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 2001; 20: 4450-4456.
68. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4: 431-436.
69. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-386.
70. Herseth JI, Refsnes M, Lag M, Schwarze PE. Role of IL-1 beta and COX2 in silicainduced IL-6 release and loss of pneumocytes in co-cultures. Toxicol In Vitro 2009; 23: 1342-1353.
71. Subbaramaiah K, Cole PA, Dannenberg AJ. Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and - independent mechanisms. Cancer Res 2002; 62: 2522-2530.
72. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002; 277: 18649-18657.
73. Gao F, Wang X, Zhu F, Wang Q, Zhang X, Guo C et al. PDCD4 gene silencing in gliomas is associated with 50CpG island methylation and unfavourable prognosis. J Cell Mol Med 2009; 13: 4257-4267.
74. Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 2008; 105: 14094-14099.
75. Moeller MJ, Soofi A, Braun GS, Li X, Watzl C, Kriz W et al. Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J 2004; 23: 3769-3779.
76. Tanoue T, Takeichi M. New insights into Fat cadherins. J Cell Sci 2005; 118: 2347-2353.
77. Braun GS, Kretzler M, Heider T, Floege J, Holzman LB, Kriz W et al. Differentially spliced isoforms of FAT1 are asymmetrically distributed within migrating cells. J Biol Chem 2007; 282: 22823-22833.
78. Tanoue T, Takeichi M. Mammalian Fat1 cadherin regulates actin dynamics and cell-cell contact. J Cell Biol 2004; 165: 517-528.
79. Hou R, Liu L, Anees S, Hiroyasu S, Sibinga NE. The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals. J Cell Biol 2006; 173: 417-429.
80. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005; 11: 937s-943ss.
81. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008; 22: 449-462.
82. Nieves-Alicea R, Colburn NH, Simeone AM, Tari AM. Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases- 2 expression. Breast Cancer Res Treat 2009; 114: 203-209.
83. Gaur AB, Holbeck SL, Colburn NH, Israel MA. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol 2011; 13: 580-590.
84. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 1995; 166: 297-301.
85. Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 2004; 23: 8135-8145.
86. Ding L, Zhang X, Zhao M, Qu Z, Huang S, Dong M et al. An essential role of PDCD4 in progression and malignant proliferation of gastrointestinal stromal tumors. Med Oncol 2012; 29: 1758-1764.
87. Wei ZT, Zhang X, Wang XY, Gao F, Zhou CJ, Zhu FL et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci 2009; 100: 1408-1413.
88. Wang X, Wei Z, Gao F, Zhang X, Zhou C, Zhu F et al. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. Anticancer Res 2008; 28: 2991-2996.
89. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u- PAR) gene expression via Sp-transcription factors. Oncogene 2007; 26: 4550-4562.
90. Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 2007; 110: 1697-1707.
91. Sen E. Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy. Drug Discov Today 2011; 16: 1044-1051.
92. Sinha S, Koul N, Dixit D, Sharma V, Sen E. IGF-1 induced HIF-1alpha-TLR9 cross talk regulates inflammatory responses in glioma. Cell Signal 2011; 23: 1869-1875.
93. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000; 60: 4926-4931.
94. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001; 61: 4375-4381.
95. Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004; 108: 43-48.
96. Eberstal S, Badn W, Fritzell S, Esbjornsson M, Darabi A, Visse E et al. Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors. Cancer Immunol Immunother 2012; 61: 1191-1199.
97. Sareddy GR, Geeviman K, Ramulu C, Babu PP. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway. J Neurooncol 2011; 106: 99-109.
98. New P. Cyclooxygenase in the treatment of glioma: its complex role in signal transduction. Cancer Control 2004; 11: 152-164.
99. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 2007; 42: 193-212.
100. Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci 2007; 3: 328-334.
101. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007; 42: 93-126.
102. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM et al. Cancer and inflammation: promise for biologic therapy. J Immunother 2010; 33: 335-351.
103. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA 1997; 94: 5826-5830.
104. Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 2000; 275: 23627-23635.